OC50 2023: Marc Forth



WHY: Former Allergan executive at helm of clinical-stage, biopharmaceutical company that aims to go public this year via a reverse merger with Priveterra Acquisition Corp. to accelerate the clinical development of its lead product, ABP-450, which is an injection to treat debilitating medical conditions in neurology, such as migraine headaches.

BY THE NUMBERS: Transaction values the combined company around $475.5 million. Priveterra’s IPO raised proceeds of $276 million.

FUTURE PLANS: Investing in trials over the next three years. Aims to double to about 20 employees by the end of the year and will ramp up significantly once its ABP-450 passes its clinical trials during the next two years and prepares for commercialization.

IN THEIR WORDS: “We’re making great progress across our late-stage clinical programs as we continue the development of ABP-450 for the treatment of multiple debilitating medical conditions.”

OC50 logo